|
|
| |
Parmi les intervenants
Bill Abernethy, Director, Global Marketing, Genzyme
Fidah Alsagoff, Director, Corporate Development, Singapore Health Services
Jean-Claude Ameisen, Directeur du Comité d'éthique de l'INSERM
Laurent Bertin, Vice-President, Prospective and Portfolio Management, sanofi-aventis
Alan Colman, Chief Executive Officer, Embryonic Stem Cell International
Marc de Garidel, Vice-président Europe de l'Ouest, Amgen International
Hervé Gisserot, Président directeur général, GlaxoSmithKline France
Marlene Haffner, Director, Office of Orphan Products Development, FDA
Damian Hine, Professor of Management, University of Queensland, Australia
Michèle Jean, Chairman of the International Bioethics Committee, UNESCO
Claudio Jommi, Head of the Osservatorio Farmaci, Bocconi University
Axel Kahn, Doyen de l'Université Paris-Descartes
Evelyn Fox Keller, Professor of epistemology, Massachusetts Institute of Technology
Philippe Kourilsky, Professeur au Collège de France
Christian Lajoux, Président directeur général, sanofi-aventis France ; Président du LEEM
Yann Le Cam, Chief Executive Officer of Eurordis, Vice Chair of the COMP at the EMEA
Pierre Le Sourd, Chief Executive Officer, Bristo-Myers Squibb France
Thomas London, Associate Director, McKinsey
Thomas Lönngren, President of the European Medicine Agency
Alex Matter, Director of the Novartis Institute of Tropical Disease
Luc Montagnier, President of the World Foundation for AIDS Research & Prevention
Stuart Schweitzer, Professor of Health Economics, UCLA School of Public Health
Françoise Simon, Professor of Marketing, Columbia University
Tomye Tierney, Vice-President, General Manager, Emerging markets, Genzyme
Fred Turner, Chairman & Chief Executive Officer, Genzyme, France
Willem Verhoofstad, Head of Project Management, Roche
Christophe Weber, Senior Vice-President, GlaxoSmithKline
Jean Zetlaoui, Vice-President, Portfolio Value Development, sanofi-aventis
|
|
